Ralph Tiedt

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition.

Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition.

Journal: Science (New York, N.Y.)

Published: July 03, 2025

Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry.

Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry.

Journal: Nature structural & molecular biology

Published: May 13, 2025

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 28, 2024

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Journal: Cell reports

Published: May 06, 2021

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.

Journal: Oncotarget

Published: April 16, 2020

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Journal: Blood

Published: April 01, 2020

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 05, 2020

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.

Journal: Science advances

Published: February 08, 2020

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

Journal: Investigational new drugs

Published: February 07, 2020

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Journal: ACS medicinal chemistry letters

Published: October 01, 2019

BET bromodomain inhibitors regulate keratinocyte plasticity.

BET bromodomain inhibitors regulate keratinocyte plasticity.

Journal: Nature chemical biology

Published: September 27, 2019

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

Journal: Journal of neuro-oncology

Published: September 10, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026